Biocon Biologics

NEW DELHI: () retail investors continued to lose their worth of investments for the fourth day after listing as the stock fell another 2 per cent on Friday to close down near all-time lows. The stock has fallen 13 per cent from its issue…

Biocon Biologics’ Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices, and health clinics Biocon Biologics’ Insugen formulations will be available to patients at all Ministry of…

New Delhi: Biocon Biologics, a subsidiary of Biocon, will file for an initial public offer (IPO) within next two years, Executive Chairperson Kiran Mazumdar-Shaw said on Monday. Biocon Biologics, which has inked a deal to acquire Viatris…

Shares of Biocon slipped 8 per cent to Rs 363.45 on the BSE in Monday’s intra-day trade after Biocon Biologics (BBL), the subsidiary of the company, announced to acquire…

Drugmaker is banking on the ramp-up of interchangeable biosimilar insulin glargine expecting the product to boost the revenue and profit growth in the next several quarters, primarily from the US market. "The launch supplies for the…

Biocon’s partner US-based Equillium Inc has expanded its ‘EQUALISE’ study in Systemic Lupus Erythematosus (SLE) and Lupus Nephritis for Itolizumab to clinical centers in India, Biocon Ltd said in a regulatory filing. Biocon Biologics, an…

On an annualised level, our biologics business grew 21% from Rs 2,315 crore to Rs 2,800 crore this fiscal. At a consolidated level, we grew 14% from Rs 6,462 crore to Rs 7,360 crore, says Kiran Mazumdar Shaw, Executive Chairperson, . The Q4…